The DOI matches its Crossref record; 203 of the 203 references it cites were found in a registry or an index.
Role of interleukin-6 in cancer progression and therapeutic resistance
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–203 of 203
Atreya, R. N., Finotto, S., Mudter, J., Mullberg, J., Jostock, T., Holtmann, M. H., Kishimoto, T., Galle, P. R., Rose‐John, S., & Neurath, M. F. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)85593-6 · Cited by 12
Zoledronic acid effects interleukin-6 expression in hormone-independent prostate cancer cell lines
Asbagh, L. A., Uzunoğlu, S., & Çal, Ç. (2008) · International braz j urol · doi:10.1590/s1677-55382008000300013 · Cited by 7
Siltuximab in transplant-ineligible patients with myeloma
Bagcchi, S. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70226-8 · Cited by 5
Cited by
The biology and function of fibroblasts in cancer
Kalluri, R. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.73 · Cited by 4,366
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,409
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Johnson, D. E., O'Keefe, R. A., & Grandis, J. R. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.8 · Cited by 3,110
Interleukins in cancer: from biology to therapy
Briukhovetska, D., Dörr, J., Endres, S., Libby, P., Dinarello, C. A., & Kobold, S. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00363-z · Cited by 781
Engineering CAR-T Cells for Next-Generation Cancer Therapy
Hong, M., Clubb, J. D., & Chen, Y. Y. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.07.005 · Cited by 639
Metadata
- Authors
- Kumari, N., Dwarakanath, B. S., Das, A., & Bhatt, A. N.
- Venue
- Tumor Biology
- Published
- 2016-06-03
- Volume
- 37
- Issue
- 9
- Pages
- 11553-11572
- ISSN
- 1010-4283 (ISSN-L)
- 1423-0380
- OpenAlex
- W2409057459
- Cited by
- 1,092
- References
- 203
- FWCI
- 27.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.